Table 1.
Inflammasomes and their activators in inflammatory bone diseases
| Activators | Disorders | Description of the activators | Inflammasomes |
|---|---|---|---|
| PAMPs | Periodontitis[[57–59] | Porphyromonas gingivalis | NLRP3, AIM2 |
| Osteomyelitis[[60–62] | Staphylococcus aureus | NLRP3 | |
| Mutations | CAPS[[63–79] | Autosomal dominant | NLRP3, NLRC4, NLRP12 |
| MAS[[11, 12, 80, 81] | Autosomal dominant | NLRC4 | |
| FMF[[82, 83] | Autosomal recessive | Pyrin | |
| DAMPs | Sterile CRMO[[22, 23] | Unknown | NLRP3 |
| Arthritis[[84–88] | Self-DNA, other DAMPs? | NLRP3, AIM2, others? | |
| Metabolic diseases, aging[[5–8, 89–91] | Purine metabolites, fatty acids, other DAMPs? | NLRP3, NLRC4, AIM2, others? | |
| Wear debris osteolysis[[3, 92, 93] | PMMA, CoCrMo, etc. | NLRP3, AIM2 | |
| Crystal-induced arthropathies[[94–97] | MSU crystals (gout), CPPD crystals (pseudogout), BCP crystals | NLRP3 |